Description

Simple

A medication that has been used to relax muscles and open airways during anesthesia for surgery.

Clinical

A nondepolarizing neuromuscular blocking agent used as an adjunct to general anesthesia to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgical procedures.

Overview

Rapacuronium was withdrawn in 2001 in many countries due to risk of fatal bronchospasm.

Pharmacology

Indication

Used in anaesthesia, to aid and enable endotracheal intubation.

Pharmacodynamic

Rapacuronium is a rapidly acting, non-depolarizing neuromuscular blocker.

Mechanism of action

Information currently not available.

Absorption

Information currently not available.

Protein binding

Variable. Plasma protein binding of rapacuronium was studied in vitro for human plasma by equilibrium dialysis. The protein binding was variable and ranged between 50% and 88%, which was at least partly due to hydrolysis of rapacuronium bromide to its 3-hydroxy metabolite. The specific plasma protei... Read more

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

141 minutes (mean)

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Rapacuronium
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
1,10-Phenanthroline
1,10-Phenanthroline may decrease the neuromuscular blocking activities of Rapacuronium.
2,5-Dimethoxy-4-ethylamphetamine
The risk or severity of Tachycardia can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Rapacuronium.
2,5-Dimethoxy-4-ethylthioamphetamine
The risk or severity of adverse effects can be increased when Rapacuronium is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamine
The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Rapacuronium.
4-Methoxyamphetamine
The risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Rapacuronium.
5-methoxy-N,N-dimethyltryptamine
The risk or severity of adverse effects can be increased when Rapacuronium is combined with 5-methoxy-N,N-dimethyltryptamine.
7-Nitroindazole
The risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Rapacuronium.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
The risk or severity of adverse effects can be increased when Rapacuronium is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Abediterol
The risk or severity of Tachycardia can be increased when Rapacuronium is combined with Abediterol.
Acepromazine
The risk or severity of adverse effects can be increased when Acepromazine is combined with Rapacuronium.
Aceprometazine
The risk or severity of adverse effects can be increased when Aceprometazine is combined with Rapacuronium.
Acetazolamide
The risk or severity of adverse effects can be increased when Acetazolamide is combined with Rapacuronium.
Acetophenazine
The risk or severity of adverse effects can be increased when Acetophenazine is combined with Rapacuronium.
Acetyldigitoxin
The risk or severity of Cardiac Arrhythmia can be increased when Rapacuronium is combined with Acetyldigitoxin.
Acetyldigoxin
The risk or severity of Cardiac Arrhythmia can be increased when Rapacuronium is combined with Acetyldigoxin.
Acetylglycinamide chloral hydrate
The risk or severity of adverse effects can be increased when Rapacuronium is combined with Acetylglycinamide chloral hydrate.
Aclidinium
The risk or severity of adverse effects can be increased when Rapacuronium is combined with Aclidinium.
Acotiamide
Acotiamide may decrease the neuromuscular blocking activities of Rapacuronium.
Adenosine
The risk or severity of Tachycardia can be increased when Adenosine is combined with Rapacuronium.
Adinazolam
The risk or severity of adverse effects can be increased when Adinazolam is combined with Rapacuronium.